Loading
Consolidation durvalumab / Non Small Cell Lung Cancer Stage III · Phase 4 Trial
ClinicalTrials.gov · August 20, 2026
Early or partial results. Treat as a signal, not a conclusion.
This is a Phase 4 feasibility study currently recruiting participants to evaluate the safety and procedural feasibility of adding surgery after chemoradiotherapy, followed by durvalumab consolidation, in patients with stage III NSCLC initially deemed unresectable. No results have been reported in this registry record.
Phase 4, Interventional, Single Group, Open label, Treatment purpose. Non-small Cell Lung Cancer Stage III; age from 18 Years. Intervention: Chemoradiotherapy plus surgery and immunotherapy. n = 38. 1 site: Netherlands.
This is a Phase 4 feasibility study currently recruiting participants to evaluate the safety and procedural feasibility of adding surgery after chemoradiotherapy, followed by durvalumab consolidation, in patients with stage III NSCLC initially deemed unresectable. No results have been reported in this registry record.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
This study is designed to test whether adding surgery after chemoradiotherapy can improve locoregional control and potentially survival in stage III NSCLC. Results, when available, may inform treatment sequencing and patient selection for this multimodal approach.
This is an ongoing Phase 4 interventional trial registration with no results posted; it describes a feasibility study of post-CRT surgery followed by durvalumab consolidation in stage III NSCLC.
As stated by the source record.
Quoted from the source exactly as published.
This study is designed to test whether adding surgery after chemoradiotherapy can improve locoregional control and potentially survival in stage III NSCLC. Results, when available, may inform treatment sequencing and patient selection for this multimodal approach.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no key findings. That is a gap in the analysis, not a judgement about the study.
Registry record from ClinicalTrials.gov (NCT06908070). This is a study registration, not published results. Lead sponsor: Idris Bahce. Recruitment status: RECRUITING. Phase: PHASE4. Study type: INTERVENTIONAL. Enrollment: 38 participants (ESTIMATED). Conditions: Non-small Cell Lung Cancer Stage III. Interventions: DRUG: Consolidation durvalumab. Primary outcome measures: The rates of severe surgical morbidity and mortality , Within 90-days of surgery; Percentage of patients with high-grade treatment-related adverse events , Within 90-days of surgery; Proportion of patients proceeding to durvalumab consolidation after surgery , Within 2 months. Brief summary: Lung cancer presents a significant treatment challenge, particularly in the heterogeneous stage III NSCLC patient population. While chemotherapy combined with high-dose radiotherapy (60 Gy in 30 fractions of 2 Gy once daily) is currently the recommended approach for unresectable stage III cases, it is associated with significant rates of locoregional and distant failures. Notably, the introduction of durvalumab consolidation therapy after chemoradiotherapy (CRT), as demonstrated in the PACIFIC study, has shown improved overall survival, primarily attributed to enhanced distant control. This improvement prompts further interest in investigating whether further improvements in locoregional control can lead to improved survival for patients. The present study aims to evaluate the feasibility of post-CRT surgery in patients with initially considered unresectable stage III (non-N3) NSCLC.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.